Dispute resolution is the US Food and Drug Administration’s preferred process for withdrawing accelerated approvals, a route that could dramatically speed up the slow and time-consuming exercise.
In its fiscal year 2023 budget congressional justification, the agency included several accelerated approval reforms among its legislative proposals,...






